Current Colorectal Cancer Reports

, Volume 7, Issue 1, pp 33–41

Prevention by Aspirin of Colorectal Adenoma Recurrence: Some Advances and Latest Results of the APACC Trial

  • Robert Benamouzig
  • Bernard Uzzan
  • Jacques Deyra
  • Antoine Martin
  • Stanislas Chaussade
Article

DOI: 10.1007/s11888-010-0079-5

Cite this article as:
Benamouzig, R., Uzzan, B., Deyra, J. et al. Curr Colorectal Cancer Rep (2011) 7: 33. doi:10.1007/s11888-010-0079-5

Abstract

In a randomized controlled trial (RCT), 272 patients were assigned to lysine acetylsalicylate 160 mg/day (n = 73) or 300 mg/day (n = 67) or placebo (n = 132). The primary end points were adenoma recurrence and adenomatous polyp burden (APB) at year 1 or 4 (last colonoscopy) and at year 4. At last colonoscopy, APB tended to be lower under aspirin 160 mg or at either dose compared with placebo (P = 0.06 and 0.07, respectively). At year 4, 55 patients had received aspirin 160 mg/d, 47,300 mg/d, and 83 placebo. APB and proportions of patients with at least one recurrent adenoma were similar in both groups. A personal history of adenomas and an initial APB higher than 10 mm predicted recurrence. Among 219 adenomas from 136 patients, 128 adenomas (58%) from 59 patients strongly expressed COX-2 assessed by immunohistochemistry, mainly adenomas larger than 10 mm (84/129 vs 44/90; P = 0.02) and adenomas showing high-grade dysplasia (22/29 vs 104/188; P = 0.04). Deep stromal initial expression of COX-2 predicted recurrence (P = 0.04). Protection by aspirin was mainly observed in patients in whom COX-2 initial expression was low (RR: 0.59; 95% CI = 0.39–0.90; P = 0.02). Aspirin decreased adenoma recurrence significantly at 1 year, marginally at year 1 or 4, and not at year 4, possibly due to attrition but also to a differential effect according to polyp natural history. In a recent patient-level meta-analysis including the four published RCTs, aspirin significantly decreased adenoma risk by 17% and risk of advanced lesions by 28%.

Keywords

Colorectal adenomaChemopreventionAcetylsalicylic acidRandomized controlled trialPlaceboCOX-2 expression

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Robert Benamouzig
    • 1
  • Bernard Uzzan
    • 2
  • Jacques Deyra
    • 3
  • Antoine Martin
    • 4
  • Stanislas Chaussade
    • 5
  1. 1.Department of Gastroenterology, AP-HPAvicenne HospitalBobignyFrance
  2. 2.Department of Pharmacology, AP-HPAvicenne HospitalBobignyFrance
  3. 3.APACC, AP-HPCochin HospitalParis Cedex 14France
  4. 4.Department of Pathology, AP-HPAvicenne HospitalBobignyFrance
  5. 5.Department of Gastroenterology, AP-HPCochin HospitalParis Cedex 14France